Clinical Trials
49 trialsA Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitean-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer
National Cancer Institute (NCI)
ABLE-22
Ferring Pharmaceuticals
Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer
National Cancer Institute (NCI)
A Study Comparing Standard Treatments in People With Non-Muscle Invasive Bladder Cancer (NMIBC)
Memorial Sloan Kettering Cancer Center
EV-309
Astellas Pharma Inc
SunRISe-2
Janssen Research & Development, LLC
SunRISe-5
Janssen Research & Development, LLC
MoonRISe-1
Janssen Research & Development, LLC
MoonRISe-3
Janssen Research & Development, LLC
BRIDGE
Eastern Cooperative Oncology Group
Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer
National Cancer Institute (NCI)
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
NRG Oncology
MK-3475-992
Merck Sharp & Dohme LLC
Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma
BeOne Medicines
Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)
AstraZeneca
Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer
AstraZeneca
Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2
Seagen Inc.
A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer
Bristol-Myers Squibb
GAIN-BCG
Alliance for Clinical Trials in Oncology
NIAGARA
AstraZeneca
CheckMate901
Bristol-Myers Squibb
A Trial of SHR-A2102 With Adebrelimab in Locally Advanced or Metastatic Urothelial Carcinoma
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
KEYNOTE-B15
Merck Sharp & Dohme LLC
NILE
AstraZeneca
KEYNOTE-866
Merck Sharp & Dohme LLC
NAUTICAL
University Health Network, Toronto
Gemcitabine Versus Water Irrigation in Upper Tract Urothelial Carcinoma
University of Texas Southwestern Medical Center
EV-302
Astellas Pharma Inc
IMvigor130
Hoffmann-La Roche
A Clinical Trail to Determine the Safety and Efficacy of the Combination of Tislelizumab With Cisplatin and Gemcitabine, With or Without Trilaciclib for Patients With Untreated Unresectable and Metastatic Urothelial Carcinoma.
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer
Mabwell (Shanghai) Bioscience Co., Ltd.
HIVEC in Patients With Non-Muscle-Invasive Bladder Cancer
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma
RemeGen Co., Ltd.
Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer
National Cancer Institute (NCI)
BIC
Corewell Health West
A Study Evaluating Toripalimab Injection Combined With Standard Chemotherapy as a First-line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma
Shanghai Junshi Bioscience Co., Ltd.
POUT
Institute of Cancer Research, United Kingdom
S0337, Gemcitabine After Surgery in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer
SWOG Cancer Research Network
Comparison of Immediate and Delayed Adjuvant Chemotherapy in Treating Patients Who Have Undergone a Radical Cystectomy for Stage III or Stage IV Transitional Cell Carcinoma of the Bladder Urothelium
European Organisation for Research and Treatment of Cancer - EORTC
Combination Chemotherapy in Treating Patients With Bladder Cancer
Alliance for Clinical Trials in Oncology
CILAB
Sanofi
Adjuvant Chemotherapy Following Radical Cystectomy to Treat Locally Advanced Bladder Cancer
Southwest Hospital, China
Cisplatin and Gemcitabine Compared With Observation in Treating Patients Who Have Undergone Surgery for Bladder Cancer
National Cancer Institute (NCI)
Cisplatin Plus Gemcitabine With or Without Paclitaxel in Treating Patients With Stage IV Urinary Tract Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Adjuvant Post-radical Cystectomy Treatment for Bladder Cancer
Cairo University
Randomized Phase III Trial of Leukine® vs Neupogen® in Patients Receiving Cisplatin & Gemcitabine for Urothelial Cancer
University of Kentucky
Instillation of Gemcitabine in Patients With Superficial Bladder Cancer
Eli Lilly and Company
Adjuvant Versus Progression-Triggered Gemcitabine Monotherapy for Locally Advanced Bladder Cancer
Association of Urologic Oncology (AUO)